IBA - Transparency notification
Louvain-la-Neuve, Belgium, December 15, 2016, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification , in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to today's capital increase (SOP exercices) causing the passive downward crossing by Capfi Delen Asset Management NV of the 3% threshold.
|Reason for the notification||Passive downward crossing of the lowest threshold further to today's capital increase (SOP exercice)|
|Persons subject to the notification requirement||IBA SA, issuer|
|Persons that dispose of voting rights||Capfi Delen Asset Management NV|
|Transaction date||15 December 2016|
|Threshold that is crossed (in %)||3% (statutory thresholds)|
|Before the transaction||After the transaction|
|Denominator||29 585 703||29 764 396|
|Voting rights (number)||889 372||889 372|
|Voting rights (%)||3.01||2.99|
|Chain of control|
* * *
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com .
For more information, please contact
Corporate Legal Counsel
+32 10 201 159